Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
- PMID: 25575620
- DOI: 10.1016/j.biopsych.2014.11.015
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Abstract
Background: After no research in humans for >40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with schizophrenia exhibit similar impairments in PPI. However, no data are available on the effects of LSD on PPI in humans.
Methods: In a double-blind, randomized, placebo-controlled, crossover study, LSD (200 μg) and placebo were administered to 16 healthy subjects (8 women, 8 men). Outcome measures included psychometric scales; investigator ratings; PPI of the acoustic startle response; and autonomic, endocrine, and adverse effects.
Results: Administration of LSD to healthy subjects produced pronounced alterations in waking consciousness that lasted 12 hours. The predominant effects induced by LSD included visual hallucinations, audiovisual synesthesia, and positively experienced derealization and depersonalization phenomena. Subjective well-being, happiness, closeness to others, openness, and trust were increased by LSD. Compared with placebo, LSD decreased PPI. LSD significantly increased blood pressure, heart rate, body temperature, pupil size, plasma cortisol, prolactin, oxytocin, and epinephrine. Adverse effects produced by LSD completely subsided within 72 hours. No severe acute adverse effects were observed.
Conclusions: In addition to marked hallucinogenic effects, LSD exerts methylenedioxymethamphetamine-like empathogenic mood effects that may be useful in psychotherapy. LSD altered sensorimotor gating in a human model of psychosis, supporting the use of LSD in translational psychiatric research. In a controlled clinical setting, LSD can be used safely, but it produces significant sympathomimetic stimulation.
Trial registration: ClinicalTrials.gov NCT01878942.
Keywords: Adverse effects; Hormones; LSD; Prepulse inhibition; Subjective effects; Sympathomimetic effects.
Copyright © 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Comment in
-
Lysergic Acid Diethylamide and Psilocybin Revisited.Biol Psychiatry. 2015 Oct 15;78(8):516-8. doi: 10.1016/j.biopsych.2015.08.003. Biol Psychiatry. 2015. PMID: 26386624 No abstract available.
Similar articles
-
Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.Neuropsychopharmacology. 2020 Feb;45(3):462-471. doi: 10.1038/s41386-019-0569-3. Epub 2019 Nov 16. Neuropsychopharmacology. 2020. PMID: 31733631 Free PMC article.
-
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.Clin Pharmacokinet. 2017 Oct;56(10):1219-1230. doi: 10.1007/s40262-017-0513-9. Clin Pharmacokinet. 2017. PMID: 28197931 Free PMC article. Clinical Trial.
-
Lysergic Acid Diethylamide and Psilocybin Revisited.Biol Psychiatry. 2015 Oct 15;78(8):516-8. doi: 10.1016/j.biopsych.2015.08.003. Biol Psychiatry. 2015. PMID: 26386624 No abstract available.
-
Modern Clinical Research on LSD.Neuropsychopharmacology. 2017 Oct;42(11):2114-2127. doi: 10.1038/npp.2017.86. Epub 2017 Apr 27. Neuropsychopharmacology. 2017. PMID: 28447622 Free PMC article. Review.
-
The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers.Hum Psychopharmacol. 2022 May;37(3):e2825. doi: 10.1002/hup.2825. Epub 2021 Nov 5. Hum Psychopharmacol. 2022. PMID: 34739739 Review.
Cited by
-
Lysergic acid diethylamide: a drug of 'use'?Ther Adv Psychopharmacol. 2016 Jun;6(3):214-28. doi: 10.1177/2045125316640440. Epub 2016 Mar 23. Ther Adv Psychopharmacol. 2016. PMID: 27354909 Free PMC article. Review.
-
Language evolution: examining the link between cross-modality and aggression through the lens of disorders.Philos Trans R Soc Lond B Biol Sci. 2021 May 10;376(1824):20200188. doi: 10.1098/rstb.2020.0188. Epub 2021 Mar 22. Philos Trans R Soc Lond B Biol Sci. 2021. PMID: 33745319 Free PMC article.
-
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics.Biology (Basel). 2023 Oct 28;12(11):1380. doi: 10.3390/biology12111380. Biology (Basel). 2023. PMID: 37997979 Free PMC article. Review.
-
The crosstalk between 5-HT2AR and mGluR2 in schizophrenia.Neuropharmacology. 2023 Jun 1;230:109489. doi: 10.1016/j.neuropharm.2023.109489. Epub 2023 Mar 6. Neuropharmacology. 2023. PMID: 36889432 Free PMC article. Review.
-
Ligand-Free Signaling of G-Protein-Coupled Receptors: Physiology, Pharmacology, and Genetics.Molecules. 2023 Aug 31;28(17):6375. doi: 10.3390/molecules28176375. Molecules. 2023. PMID: 37687205 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
